Emyria's Quarterly Report Highlights

Emyria Limited (ASX: $EMD) has reported a positive net cash flow from operating activities of $724k and steady clinical billings of $967k in its quarterly report for the period ending 31st March 2024. The company, dedicated to developing new treatments for mental health and select neurological conditions, received its first Authorised Prescriber approval for the lead psychiatrist of drug-assisted therapy programs. Additionally, subsequent to the quarter end, Emyria secured firm bids for $2.3m via a placement to new and existing sophisticated investors to support scale-up and payer engagement for Emyria's Empax Centre.

Executive Commentary

Our first Authorised Prescriber approval this quarter highlights our ability to navigate the key regulatory and clinical complexities required to establish a distinct clinical service dedicated to the real-world evaluation of promising new treatments for mental health conditions and with significant commercial potential. The recent launch of the Empax Centre, alongside improving commercial performance, further supports our innovation pipeline and we are well-set for a productive remainder of the year.

Quarterly Report Summary

Emyria Limited (ASX: $EMD) has made significant strides in advancing PTSD treatment infrastructure, with the first Authorised Prescriber approval and securing firm bids for scale-up and payer engagement for Emyria's Empax Centre. The company is dedicated to addressing the unmet needs of approximately 1 million Australian adults living with PTSD by developing safe, effective, and scalable treatment options. Emyria's innovation pipeline highlights include conducting clinical trials evaluating MDMA-AT for PTSD, developing MDMA analogues with the University of Western Australia and the National Institute of Health, and successfully completing safety assessments for drug candidates RX7/9. The company's ambitions and goals are focused on providing innovative treatments for PTSD and other neurological conditions, supported by its clinical expertise and operational setup.